WO2005087292A9 - Method for obtaining an intermediate fraction in the centrifugal separation of blood - Google Patents

Method for obtaining an intermediate fraction in the centrifugal separation of blood

Info

Publication number
WO2005087292A9
WO2005087292A9 PCT/US2005/008175 US2005008175W WO2005087292A9 WO 2005087292 A9 WO2005087292 A9 WO 2005087292A9 US 2005008175 W US2005008175 W US 2005008175W WO 2005087292 A9 WO2005087292 A9 WO 2005087292A9
Authority
WO
WIPO (PCT)
Prior art keywords
syringe
centrifugation
buffy coat
container
plasma
Prior art date
Application number
PCT/US2005/008175
Other languages
French (fr)
Other versions
WO2005087292A1 (en
Inventor
Richard Lariviere
Andrew Mcgillicuddy
James R Ellsworth
Original Assignee
Harvest Technologies Corp
Richard Lariviere
Andrew Mcgillicuddy
James R Ellsworth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvest Technologies Corp, Richard Lariviere, Andrew Mcgillicuddy, James R Ellsworth filed Critical Harvest Technologies Corp
Publication of WO2005087292A1 publication Critical patent/WO2005087292A1/en
Publication of WO2005087292A9 publication Critical patent/WO2005087292A9/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02Blood transfusion apparatus
    • A61M1/0272Apparatus for treatment of blood or blood constituents prior to or for conservation, e.g. freezing, drying or centrifuging
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02Blood transfusion apparatus
    • A61M1/029Separating blood components present in distinct layers in a container, not otherwise provided for
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/20Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/204Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically connected to external reservoirs for multiple refilling
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M5/315Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/31Details
    • A61M2005/3128Incorporating one-way valves, e.g. pressure-relief or non-return valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/04Liquids
    • A61M2202/0413Blood
    • A61M2202/0427Platelets; Thrombocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00Special media to be introduced, removed or treated
    • A61M2202/04Liquids
    • A61M2202/0413Blood
    • A61M2202/0439White blood cells; Leucocytes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00Moving or stopping fluids
    • B01L2400/04Moving fluids with specific forces or mechanical means
    • B01L2400/0475Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0478Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure pistons
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01LCHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5021Test tubes specially adapted for centrifugation purposes

Definitions

  • This invention relates to the art of fluid fractionalization.
  • this invention relates to a system for obtaining blood fractions of intermediate density.
  • BACKGROUND ART It is known to separate blood centrifugally into several fractions.
  • blood is placed in one chamber of a disposable unit that has two adjacent chambers.
  • the disposable unit is then placed in a centrifuge, and the centrifuge operated to separate the blood into fractions.
  • the disposable unit is then tilted to allow lighter fractions to decant into the second chamber.
  • the lighter fractions comprise plasma and a buffy coat, which includes the platelets and white blood cells.
  • the buffy coat lies at the interface of the lighter plasma and the heavier red blood cells and is, thus, an intermediate fraction.
  • the plasma and buffy coat fractions that have been decanted into the second chamber are subjected to a second centrifugation whereby the buffy coat is caused to lie at the bottom of the second chamber.
  • the buffy coat can be removed from the second chamber after the second centrifugation by passing a cannula through the upper layer containing only plasma and into the buffy coat and withdrawing the buffy coat into a syringe.
  • fractions of intermediate density are easily separated from a mixture by using two containers, each of which is capable of expressing one or more fractions in such a manner that the desired fraction of intermediate density can be obtained.
  • whole blood is obtained from a patient, and the desired fraction to be separated from the whole blood is the buffy coat, the fraction of blood that includes platelets, among other components.
  • the buffy coat is obtained from the whole blood by introducing the whole blood into a first container, preferably a first syringe, from which a separated fraction may be expressed into a second container.
  • the first syringe is placed in a centrifuge in an orientation whereby the heavier fraction containing red blood cells is caused to accumulate adjacent the end of the syringe having a plunger.
  • the lighter fractions containing plasma and the buffy coat then accumulate in the region adjacent the input/discharge end of the syringe.
  • a separator of appropriate density be employed, which separator automatically positions itself at the interface between the buffy coat and the red blood cells and reduces mixing of these layers after centrifugation.
  • a syringe is a preferred container because its input/discharge end is conical, which is advantageous during discharge because it provides increased control over discharge of fluids in the region of the interface between plasma and red blood cells.
  • Containers other than a syringe may be employed, such as an evacuated tube that draws fluid into the tube under reduced pressure.
  • the first centrifugation of the whole blood is just enough to separate plasma from red blood cells. This first spin provides mainly two separated fractions, platelet rich plasma and red blood cells. As is known, however, intermediate fractions begin to form even during the first spin. Thus, the buffy coat begins to form during this first spin but is not large or well formed.
  • the syringe plunger is actuated to express the platelet rich plasma and the initial layers of the intermediate fractions, including the buffy coat, into a second container, preferably a syringe.
  • a second container preferably a syringe.
  • the second syringe is then placed in a centrifuge such that the heavier buffy coat accumulates in the region immediately adjacent the discharge end and the platelet poor plasma accumulates adjacent the plunger. This allows the buffy coat and any desired quantity of plasma to be expressed by actuation of the plunger.
  • the process is sterile because the syringes are sterile and the fluids are not exposed to the ambient during the process.
  • Figure 1 is a side view of the first syringe illustrating the first step in a preferred method according to the invention.
  • Figure 2A is a side view of two syringes connected to each other at the beginning of a further step in the preferred method according to the invention.
  • Figure 2B is a side view of the two syringes shown in figure 2 A at the completion of the further step in the preferred method according to the invention.
  • Figure 3 is a side view of a second syringe showing a still further step in the preferred method according to the invention.
  • figure 1 illustrates a syringe 2 into which a quantity of whole blood has been drawn.
  • Syringe 2 may be a known syringe having a plunger 4 and a plunger handle 6 or may be a custom container into which the quantity of blood is placed.
  • the whole blood is drawn into the syringe by moving the plunger away from the tip 8 of the syringe.
  • the tip 8 is preferably attached directly to a needle through which the blood is drawn from the patient.
  • the tip 8 may be inserted into a separate container having blood previously drawn from the patient.
  • the syringe 2 includes a conical section 10 adjacent the tip 8, and that the tip 8 is the input/discharge port of the syringe and generally includes a Luer-type connector for detachable connection to another syringe, as will be described below, or to tubes and the like.
  • the syringe 2 includes a floating element 12, which is configured and made of material having a density whereby it assumes a position wherein the surface closest the tip lies just below the interface of the platelet rich plasma and the red blood cells after a first centrifugation of the blood.
  • the syringe 2 may be a known syringe modified by addition of the floating element 12.
  • the syringe 2 having whole blood therein is placed in a centrifuge (not illustrated) such that the forces arising from centrifugation are in the direction illustrated by the "G force" arrow in the figure.
  • the centrifuge is then operated in a "soft spin” to separate the whole blood into a red-blood-cell fraction 14, a platelet-rich-plasma fraction 14, and an initial, thin layer of the buffy coat fraction 18.
  • the syringe 2 is placed in the centrifuge in an orientation whereby the plasma layer 16 forms adjacent the input/discharge end of the syringe 2 during centrifugation.
  • a known centrifuge may be used for the processes described herein, the only major change being that its diameter be large enough to accommodate the handle 6.
  • the syringe is constructed such that the handle is connected to the plunger by a detachable connector, such as a screw thread, a clip, or the like whereby may be removed or placed in an orientation that does not extend appreciably from the end of the syringe.
  • Figures 2 A and 2B illustrate a further step of the preferred process according to the invention.
  • first syringe 2 is connected to the input/discharge end of a second syringe 20 by connecting the tip 8 of the first syringe to the tip 22 of the second syringe by a connector 24, e.g., a Luer connector.
  • a connector 24 e.g., a Luer connector.
  • the plunger 4 of syringe 2 is actuated by pushing on handle 6 to force the plasma 16 and buffy coat 18 into the syringe 20, leaving the red blood cells 14 in syringe 2.
  • the initial buffy coat layer may mix with the platelet rich plasma during the transfer illustrated in figures 2 A and 2B.
  • the important separation at this stage is between the red blood cells and the remaining fractions, and it may be desirable to intentionally mix the initial buffy coat layer with the plasma, as by shaking the syringe, to ensure that the majority of the cells of the buffy coat are transferred to the second syringe with the plasma.
  • the floating disc 12 reduces mixing between the red blood cells and the plasma during handling of the syringe after the first centrifugation. It will be appreciated further that friction with the side of the syringe tends to cause the central portion of the fluid to be expressed first but that the presence of the disc 12 will prevent the red blood cell layer from pushing through the plasma layer during expression of the plasma.
  • the disc 12 will engage the conical end of the syringe 2, and it is preferable that the disc be configured to provide a passage between its periphery and the inside wall of the syringe, e.g., by providing flattened sections on the edge of the disc. This allows cells to pass in both directions during centrifugation but also allows red blood cells to pass toward the discharge end after engagement between the disc and the conical portion to ensure expression of the entire plasma layer by filling the conical portion with red blood cells. Because the tapered configuration allows control over the expression this is easily accomplished.
  • Figure 3 illustrates a further step in the process wherein syringe 20 is placed in a centrifuge in an orientation whereby the buffy coat will accumulate adjacent the input/discharge end 30 of syringe 20. This is accomplished, in essence, by placing syringe 20 in the centrifuge in an orientation that is opposite to the orientation of syringe 2 in the centrifuge. The centrifugal forces on syringe 20 are illustrated in figure 3 by the "G Force" arrow. [0024] After centrifugation as illustrated in figure 3, a buffy coat layer 18 forms adjacent the discharge tip 22, and this may be expressed along with a desired volume of plasma by actuation of the plunger 26. If the buffy coat is discharged with a desired volume of plasma platelet-rich plasma having a desired increase in concentration over native levels is obtained. . [0025] Modifications within the scope of the appended claims will be apparent to those of skill in the art.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • External Artificial Organs (AREA)

Abstract

A method for obtaining an intermediate fraction (18) from a fluid includes the steps of introducing the fluid to a first container (2) and centrifuging the fluid to separate a first fraction (14) from the fluid. The remainder of the fluid is then transferred to a second container (20) and placed in a centrifuge such that the intermediate fraction (18) will form adjacent a discharge port (22) of the second container (20). The intermediate fraction (18) may then be expressed easily. A kit according to the invention includes the two containers.

Description

METHOD FOR OBTAINING AN INTERMEDIATE FRACTION IN THE CENTRIFUGAL SEPARATION OF BLOOD TECHNICAL FIELD [0001] This invention relates to the art of fluid fractionalization. In particular, this invention relates to a system for obtaining blood fractions of intermediate density. BACKGROUND ART [0002] It is known to separate blood centrifugally into several fractions. In the system described in United States Patent 5,707,331, blood is placed in one chamber of a disposable unit that has two adjacent chambers. The disposable unit is then placed in a centrifuge, and the centrifuge operated to separate the blood into fractions. The disposable unit is then tilted to allow lighter fractions to decant into the second chamber. In the preferred embodiment, the lighter fractions comprise plasma and a buffy coat, which includes the platelets and white blood cells. The buffy coat lies at the interface of the lighter plasma and the heavier red blood cells and is, thus, an intermediate fraction. In the Wells system, the plasma and buffy coat fractions that have been decanted into the second chamber are subjected to a second centrifugation whereby the buffy coat is caused to lie at the bottom of the second chamber. [0003] In the Wells system, the buffy coat can be removed from the second chamber after the second centrifugation by passing a cannula through the upper layer containing only plasma and into the buffy coat and withdrawing the buffy coat into a syringe. [0004] The above process requires sophisticated hardware capable of performing several complicated steps and also requires significant human interaction in the withdrawing of the buffy coat. SUMMARY OF THE INVENTION [0005] In accordance with the invention, fractions of intermediate density are easily separated from a mixture by using two containers, each of which is capable of expressing one or more fractions in such a manner that the desired fraction of intermediate density can be obtained. [0006] In the preferred embodiment, whole blood is obtained from a patient, and the desired fraction to be separated from the whole blood is the buffy coat, the fraction of blood that includes platelets, among other components. The buffy coat is obtained from the whole blood by introducing the whole blood into a first container, preferably a first syringe, from which a separated fraction may be expressed into a second container. The first syringe is placed in a centrifuge in an orientation whereby the heavier fraction containing red blood cells is caused to accumulate adjacent the end of the syringe having a plunger. The lighter fractions containing plasma and the buffy coat then accumulate in the region adjacent the input/discharge end of the syringe. It is also preferred that a separator of appropriate density be employed, which separator automatically positions itself at the interface between the buffy coat and the red blood cells and reduces mixing of these layers after centrifugation. [0007] A syringe is a preferred container because its input/discharge end is conical, which is advantageous during discharge because it provides increased control over discharge of fluids in the region of the interface between plasma and red blood cells. Containers other than a syringe may be employed, such as an evacuated tube that draws fluid into the tube under reduced pressure. [0008] The first centrifugation of the whole blood is just enough to separate plasma from red blood cells. This first spin provides mainly two separated fractions, platelet rich plasma and red blood cells. As is known, however, intermediate fractions begin to form even during the first spin. Thus, the buffy coat begins to form during this first spin but is not large or well formed. After the first centrifugation of the whole blood, the syringe plunger is actuated to express the platelet rich plasma and the initial layers of the intermediate fractions, including the buffy coat, into a second container, preferably a syringe. This is accomplished in the preferred embodiment by connecting the input/output ends of the two syringes together with a Luer connector. [0009] The second syringe is then placed in a centrifuge such that the heavier buffy coat accumulates in the region immediately adjacent the discharge end and the platelet poor plasma accumulates adjacent the plunger. This allows the buffy coat and any desired quantity of plasma to be expressed by actuation of the plunger. [0010] It will be appreciated that the process is sterile because the syringes are sterile and the fluids are not exposed to the ambient during the process. [0011] It is therefore an object of the invention to provide a simple, sterile process for the separation of an intermediate fluid fraction by centrifugation. [0012] It is a further object of the invention to provide a process for obtaining an intermediate fluid fraction by centrifugation, wherein a fluid is placed in a first container, a first fraction containing the intermediate fraction is separated by centrifugation and transferred to a second container, the intermediate fraction is separated from the first fraction by centrifugation such that it is positioned adjacent the outlet of the second container, and the intermediate fraction is then expressed from the second container. BRIEF DESCRIPTION OF THE DRAWINGS [0013] Figure 1 is a side view of the first syringe illustrating the first step in a preferred method according to the invention. [0014] Figure 2A is a side view of two syringes connected to each other at the beginning of a further step in the preferred method according to the invention. [0015] Figure 2B is a side view of the two syringes shown in figure 2 A at the completion of the further step in the preferred method according to the invention. [0016] Figure 3 is a side view of a second syringe showing a still further step in the preferred method according to the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT [0017] With reference to the drawings, figure 1 illustrates a syringe 2 into which a quantity of whole blood has been drawn. Syringe 2 may be a known syringe having a plunger 4 and a plunger handle 6 or may be a custom container into which the quantity of blood is placed. In the embodiment shown, the whole blood is drawn into the syringe by moving the plunger away from the tip 8 of the syringe. The tip 8 is preferably attached directly to a needle through which the blood is drawn from the patient. As well, the tip 8 may be inserted into a separate container having blood previously drawn from the patient. It will be appreciated that the syringe 2 includes a conical section 10 adjacent the tip 8, and that the tip 8 is the input/discharge port of the syringe and generally includes a Luer-type connector for detachable connection to another syringe, as will be described below, or to tubes and the like. [0018] The syringe 2 includes a floating element 12, which is configured and made of material having a density whereby it assumes a position wherein the surface closest the tip lies just below the interface of the platelet rich plasma and the red blood cells after a first centrifugation of the blood. The syringe 2 may be a known syringe modified by addition of the floating element 12. [0019] In accordance with a first step of a method according to the invention, the syringe 2 having whole blood therein is placed in a centrifuge (not illustrated) such that the forces arising from centrifugation are in the direction illustrated by the "G force" arrow in the figure. The centrifuge is then operated in a "soft spin" to separate the whole blood into a red-blood-cell fraction 14, a platelet-rich-plasma fraction 14, and an initial, thin layer of the buffy coat fraction 18. It will be appreciated that the syringe 2 is placed in the centrifuge in an orientation whereby the plasma layer 16 forms adjacent the input/discharge end of the syringe 2 during centrifugation. [0020] A known centrifuge may be used for the processes described herein, the only major change being that its diameter be large enough to accommodate the handle 6. Alternatively, the syringe is constructed such that the handle is connected to the plunger by a detachable connector, such as a screw thread, a clip, or the like whereby may be removed or placed in an orientation that does not extend appreciably from the end of the syringe. [0021] Figures 2 A and 2B illustrate a further step of the preferred process according to the invention. As shown in figure 2 A, the input/discharge end of first syringe 2 is connected to the input/discharge end of a second syringe 20 by connecting the tip 8 of the first syringe to the tip 22 of the second syringe by a connector 24, e.g., a Luer connector. Then, as illustrated in figure 2B, the plunger 4 of syringe 2 is actuated by pushing on handle 6 to force the plasma 16 and buffy coat 18 into the syringe 20, leaving the red blood cells 14 in syringe 2. It will be appreciated that the initial buffy coat layer may mix with the platelet rich plasma during the transfer illustrated in figures 2 A and 2B. The important separation at this stage is between the red blood cells and the remaining fractions, and it may be desirable to intentionally mix the initial buffy coat layer with the plasma, as by shaking the syringe, to ensure that the majority of the cells of the buffy coat are transferred to the second syringe with the plasma. [0022] The floating disc 12 reduces mixing between the red blood cells and the plasma during handling of the syringe after the first centrifugation. It will be appreciated further that friction with the side of the syringe tends to cause the central portion of the fluid to be expressed first but that the presence of the disc 12 will prevent the red blood cell layer from pushing through the plasma layer during expression of the plasma. Also at the end of the expression of the plasma fraction, the disc 12 will engage the conical end of the syringe 2, and it is preferable that the disc be configured to provide a passage between its periphery and the inside wall of the syringe, e.g., by providing flattened sections on the edge of the disc. This allows cells to pass in both directions during centrifugation but also allows red blood cells to pass toward the discharge end after engagement between the disc and the conical portion to ensure expression of the entire plasma layer by filling the conical portion with red blood cells. Because the tapered configuration allows control over the expression this is easily accomplished. [0023] Figure 3 illustrates a further step in the process wherein syringe 20 is placed in a centrifuge in an orientation whereby the buffy coat will accumulate adjacent the input/discharge end 30 of syringe 20. This is accomplished, in essence, by placing syringe 20 in the centrifuge in an orientation that is opposite to the orientation of syringe 2 in the centrifuge. The centrifugal forces on syringe 20 are illustrated in figure 3 by the "G Force" arrow. [0024] After centrifugation as illustrated in figure 3, a buffy coat layer 18 forms adjacent the discharge tip 22, and this may be expressed along with a desired volume of plasma by actuation of the plunger 26. If the buffy coat is discharged with a desired volume of plasma platelet-rich plasma having a desired increase in concentration over native levels is obtained. . [0025] Modifications within the scope of the appended claims will be apparent to those of skill in the art.

Claims

We claim: 1. A method for separating a blood fraction contaiiiing platelets from whole blood comprising the steps of: introducing said whole blood into a first syringe, subjecting said first syringe to centrifugation such that plasma accumulates adjacent a discharge end of said first syringe, transferring said plasma and a buffy coat fraction into a second syringe, subjecting said second syringe to centrifugation such that said buffy coat accumulates adjacent a discharge end of said second syringe. 2. A method according to claim 1 further comprising the step of expressing said buffy coat. 3. A method according to claim 2 further comprising the step of expressing a predetermined volume of plasma with said buffy coat. 4. A method according to claim 1 wherein said step of transferring comprises connecting a discharge port of said first syringe to an input port of said second syringe. 5. A kit for obtaining an intermediate fraction from a fluid by centrifugation comprising, a first container forming a cavity and having a discharge port for expressing fluids from said cavity, said first container having a floating disc therein for assuming a position during centrifugation near the boundary of first and second fractions of said fluid during centrifugation, a second container having an input port and a discharge port for discharging said intermediate fraction after centrifugation, and a connector for connecting said discharge port of said first container to said input port of said second container. 6. A kit according to claim 5 wherein said first and second containers are syringes.
PCT/US2005/008175 2004-03-11 2005-03-11 Method for obtaining an intermediate fraction in the centrifugal separation of blood WO2005087292A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55177304P 2004-03-11 2004-03-11
US60/551,773 2004-03-11

Publications (2)

Publication Number Publication Date
WO2005087292A1 WO2005087292A1 (en) 2005-09-22
WO2005087292A9 true WO2005087292A9 (en) 2005-11-17

Family

ID=34975349

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/008175 WO2005087292A1 (en) 2004-03-11 2005-03-11 Method for obtaining an intermediate fraction in the centrifugal separation of blood

Country Status (1)

Country Link
WO (1) WO2005087292A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927563B1 (en) 2009-10-13 2011-04-19 Cytomedix, Inc. Kit for separation of biological fluids
ES1073745Y (en) * 2011-01-19 2011-05-06 Ventosa Enric Jorda DEVICE FOR EXTRACTION AND OBTAINING BLOOD PLASMA AND / OR FAT
KR101445322B1 (en) 2013-06-24 2014-10-01 서울대학교산학협력단 Method of centrifugal separation
CN105586248B (en) * 2016-01-25 2017-10-24 上海东富龙科技股份有限公司 Special stem cell rapid extraction equipment
WO2020163105A1 (en) 2019-02-06 2020-08-13 Hanuman Pelican, Inc. Apparatus and methods for concentrating platelet-rich plasma
EP4181855A4 (en) * 2020-07-15 2023-10-25 PRP Technologies, Inc. Device, kit and methods for creating platelet rich plasma
US11135580B1 (en) 2020-07-15 2021-10-05 Prp Technologies Inc Device, kit and methods for creating platelet rich plasma
US20240293057A1 (en) * 2021-11-11 2024-09-05 Prp Technologies Inc Specimen collection device

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3972812A (en) * 1975-05-08 1976-08-03 Becton, Dickinson And Company Blood serum separation filter disc
US6123687A (en) * 1996-10-30 2000-09-26 Cohesion Technologies, Inc. Cell separation device and metering syringe
ATE337806T1 (en) * 1999-07-08 2006-09-15 Implant Innovations Inc SYRINGE KIT FOR THROMBOCYTE CONCENTRATION AND PROCEDURE
AU2002346247B2 (en) * 2001-06-06 2007-04-26 Perfusion Partners & Associates, Inc. Centrifuge tube assembly

Also Published As

Publication number Publication date
WO2005087292A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
US8163184B2 (en) Apparatus and method for separating and concentrating fluids containing multiple components
WO2005087292A9 (en) Method for obtaining an intermediate fraction in the centrifugal separation of blood
US7374678B2 (en) Apparatus and method for separating and concentrating fluids containing multiple components
US7922972B2 (en) Method and apparatus for separating fluid components
US8950586B2 (en) Methods and apparatus for isolating platelets from blood
EP3031525B1 (en) Apparatus and method for separating and concentrating fluids containing multiple components
US11759775B2 (en) Device, kit and methods for creating platelet rich plasma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase